N@N

FISHERS, Indiana--([ BUSINESS WIRE ])--Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce that Manhattan Isotope Technology, with the support of Positron, has executed a Memorandum of Understanding with the ARRONAX Cyclotron Facility in Nantes, France. Manhattan Isotope and ARRONAX will collaborate on production of strontium-82 and other medical radionuclides.

As previously announced Positron has entered into a binding Letter of Intent with Manhattan Isotope Technology LLC that will make MIT a wholly owned subsidiary of Positron pending upon final transaction closing. ARRONAX stands for Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic. ARRONAX GIP, a French GIP (Groupement daIntrt Public) operates a 70 MeV, cyclotron and associated support facilities. Arronax is located in Nantes on the campus of the university hospital and the ICO cancer center.

ARRONAX has made a critical investment for increasing the global supply of medical radioisotopes. ARRONAX is one of only a small number of global accelerator facilities which possess the requisite proton beam characteristics for strontium-82 production. Leading the collaboration is Dr. Jacques Barbet, director of ARRONAX GIP, and Jason Kitten president for MIT. The MOU also calls for collaboration of other high energy/high current medical radioisotopes such as germanium-68.

The parties involved expect Sr-82 validation samples will begin arriving from Arronax at the Lubbock, TX processing facility in early 2012 with the filing of Manhattan Isotope's Drug Master File with the US FDA in the spring of 2012. Currently the only supplier of Active Pharmaceutical Ingredient grade strontium-82 in the United States is the US Department of Energy. MIT LLC President, Jason Kitten commented upon the significance of the MOU, aWorking with the high caliber scientists at ARRONAX and their cutting-edge high power cyclotron is truly a tremendous growth opportunity for Sr-82 supply. We fully expect that the collaboration of ARRONAX and MIT will expand the global supply of Sr-82; a supply that is very limited and in great demand by the medical community.a

As of the date of this press release, Positron has entered into a binding LOI however has not yet entered into a definitive agreement for the acquisition of Manhattan Isotope Technology.

About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine. Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as aRisk Factorsa in our filings with the Securities and Exchange Commission.